Oncobone Ventures Ltd. and Origenis GmbH have signed a framework agreement to develop novel therapies targeting cancer bone metastasis. Origenis leverages its artificial intelligence (AI)-driven technology platform Molmind-Moresystem-Brainstorm to design innovative targeted small-molecule therapies.
Researchers from Caedo Oncology AS presented the discovery and preclinical characterization of CO-005, a novel anti-CD47 fusion protein being developed for the treatment of lymphoma.
Adcendo ApS has closed an oversubscribed $135 million series B financing round to support its development of first-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need.
When it comes to cell therapy, Alloplex Biotherapeutics Inc. CEO Frank Borriello said he believes that autologous, personalized therapy is the only thing that makes sense. “The allure of an off-the-shelf therapy has been such a magnet. It sucked in a lot of companies into that dream, and I'm sorry to say, it hasn't really worked out for them,” he told BioWorld. Instead, Borriello said he envisioned a cell training platform that doesn’t just tweak a single immune pathway but instead harnesses multiple immune pathways to turn the tables on cancer.
Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and inflammatory bowel disease.
Bright Biologics LLC reported the discovery and preclinical evaluation of BB-203, an anti-PD-L1/anti-VEGF bispecific antibody (Ab) being developed for the treatment of cancer.
Transposon Therapeutics Inc. has acquired a portfolio of novel nucleoside analogues from Primefour Therapeutics Inc. for the targeted treatment of pancreatic cancer, certain other solid tumors and hematologic cancers.
RSS
